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TBackground. Animal data demonstrate that intracardiac
patches of decellularized porcine small intestine sub-
mucosa (CorMatrix; CorMatrix Cardiovascular, Inc,
Atlanta, GA) become repopulated with native cells, sug-
gesting the possibility of a substrate for regenerative
tissue in humans. We report the only prospective series to
date of explanted CorMatrix patches placed in infants
with congenital heart disease.
Methods. CorMatrix patches were implanted as the
hemi-Fontan baffle in patients during their second stage
of palliation. The patch material was explanted as part of
the standard Fontan operation. Specimens were analyzed
with the use of hematoxylin and eosin, Movat pentach-
rome, and trichrome stains.
Results. Of the 12 implantations, 10 specimens were
explanted. Two patients did not undergo FontanAccepted for publication March 22, 2016.
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Surgeons, Phoenix, AZ, Jan 23–27, 2016.
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Published by Elsevierbecause of unfavorable hemodynamics. Acellular
material, chronic inflammation, fibrosis, and foreign
body giant cell reaction was seen in all explanted
patches. Also noted in explanted specimens was
calcification (n [ 2), elastic fibers (n [ 2), and
eosinophils (n [ 2). No explanted CorMatrix material
showed evidence of ingrowth of native cells or trans-
formation into cardiac tissue at a median of 21 months
after implantation.
Conclusions. Although the CorMatrix remained pliable
and most did not exhibit calcification, these intracardiac
patches did not show evidence of native heart tissue
ingrowth at a median of 21 months in vivo.
(Ann Thorac Surg 2016;102:1329–35)
 2016 by The Society of Thoracic Surgeonshe ability to replace damaged or absent heart struc-Ttures with the patient’s own tissue remains one of
the ultimate, but as of yet unachieved, goals of congenital
heart surgeons. Regenerated native tissue, whether culti-
vated outside the body and implanted or developed over
time on an implanted biological scaffold, would have many
advantages. These advantages include durability and the
potential for growth, important in the pediatric population.
One such scaffold, porcine small intestinal submucosa
extracellular matrix (SIS ECM), has shown promise in
regenerating native tissue. The ECM is implanted and by a
process of ingrowth of native cells may be theoretically
transformed into native tissue. CorMatrix (CorMatrix
Cardiovascular, Inc, Atlanta, GA) is a commercially avail-
able ECM product that is approved by the Food and Drug
Administration for use as a pericardial replacement and as
an intracardiac patch.
Animal studies have shown remodeling of CorMatrix
patches into myocardial tissue with contractile properties[1]. However, recent retrospective human studies have
had disappointing results [2–4]. Of all available studies to
examine explanted CorMatrix patches used for intracar-
diac use in congenital heart disease, none have shown
native tissue ingrowth [2–5]. Prior studies are limited by
their retrospective nature, heterogeneity of implant sites,
and short times in vivo [2–4]. To our knowledge, the
current study represents the first prospective histologic
study of CorMatrix for intracardiac use in children with
congenital heart disease.
The purpose of this study was to describe the histo-
pathologic process of a prospective series of explanted
CorMatrix patches used as a hemi-Fontan baffle in chil-
dren undergoing routine single-ventricle palliation.Material and Methods
The University of Michigan Medical School Institutional
Review Board approved this study. Informed, written
consent was obtained from all patients by their parents or
legal representative.
Study Population
The medical records for consecutive patients scheduled
for stage 2 palliation for a single-ventricle lesion between
June 1, 2012, and February 1, 2013. at C.S. Mott Children’s0003-4975/$36.00
http://dx.doi.org/10.1016/j.athoracsur.2016.03.086
Fig 1. (A) Hemi-Fontan patch baffle
location within the right atrium. The
patch separates the superior vena caval/
pulmonary artery junction from the body
of the right atrium. (B) Patch removal at
Fontan operation. (Reprinted with
permission from Elsevier from Bove EL,
Mosca RS. Surgical repair of the hypo-
plastic left heart syndrome. Prog Pediatr
Cardiol 1996;5:23–35.)
Fig 2. (A) Control; collagen and ghost outlines of nuclei are shown.
(Hematoxylin and eosin; 10.) (B) Control; connective tissue with
collagen stained blue. (Trichrome; 10.)
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to hemi-Fontan procedure (HFP) were approached for
parental consent. Enrollment was closed after the
recruitment of 12 patients.
Operative Details
On the basis of institutional preference, a modified HFP is
performed for stage 2 palliation whenever anatomically
possible.Our technique isdescribedelsewhere [6].Avariety
of patch materials are available for routine use for intra-
cardiac baffle creation, including polytetrafluoroethylene,
bovine pericardium, pulmonary homograft, autologous
pericardium, and decellularized porcine small intestine
submucosa (CorMatrix; CorMatrix Cardiovascular Inc).
In this study, all patients received circular 4-ply CorMa-
trix patches that measured approximately 20  20 mm
implanted as the standard hemi-Fontan baffle. The baffles
were sutured with polypropylene monofilament in a
running fashion completelywithin the right atriumbeneath
the superior vena caval-pulmonary artery connection
(Figs 1A, 1B). Therefore, the entire circumference of the
CorMatrix patch was in contact with the right atrial wall.
After operation, patients received routine postoperative
care. In general, the baffles were exposed to low (<20 mm
Hg) pressures while in vivo. When clinically appropriate
according to institutional criteria, patients underwent
completion lateral-tunnel Fontan. As a routine part of the
Fontan operation, the previously implanted CorMatrix
patches were excised (Fig 1B).
Histologic Examination
Explanted CorMatrix patches were fixed in 10% neutral-
buffered formalin and embedded in paraffin. Sections
5-mm thick were stained with hematoxylin and eosin,
Masson’s trichrome, and Movat pentachrome stains. The
histologic examination was evaluated for evidence of
native tissue ingrowth, specifically any tissue resembling
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Table 1. Clinical Characteristics of Study Population (n ¼ 12)
Characteristic Value*
Male sex 9 (75)
Diagnosis
HLHS 7 (58)
DILV 1 (8)
DORV, HRV, PS 1 (8)
Unbalanced AVSD, HLV, DORV, heterotaxy,
dextrocardia, interrupted IVC
1 (8)
DIRV, DORV 1 (8)
DORV, unbalanced AVSD, HLV 1 (8)
Operation at implant
HFP 10 (83)
HFP/Kawashima 2 (17)
Operation at explant (n ¼ 10)
Fontan 10 (100)
Patch not explanted 2 (17)
Median age at implant, months 6
Median age at explant, months 27
Median time in vivo, months 21
* Values may not sum to expected total because of rounding.
Data are n (%) unless otherwise noted.
AVSD ¼ atrioventricular septal defect; DILV ¼ double inlet left
ventricle; DIRV ¼ double inlet right ventricle; DORV ¼ double
outlet right ventricle; HFP ¼ hemi-Fontan procedure; HLHS ¼
hypoplastic left heart syndrome; HLV ¼ hypoplastic left
ventricle; HRV ¼ hypoplastic right ventricle; IVC ¼ inferior vena
cava; PS ¼ pulmonary stenosis.
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the histopathologic results were recorded. An unused
CorMatrix patch was analyzed as a control after being
prepared according to the manufacturer’s instructions
(Figs 2A, 2B).pa
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CorMatrix hemi-Fontan patches were implanted in 12
infants, ranging in age from 4 to 8 months (Table 1).
Time spent in vivo ranged from 18 to 26 months
(median, 21 months). Two patients did not undergo
completion Fontan because of unfavorable
hemodynamics.
Fibrosis, acellular material, chronic inflammation, and
foreign body giant cell reaction were seen in all
explanted specimens (Table 2; Figs 3A, 3B). Disorga-
nized elastic fibers (2 specimens), dystrophic calcifica-
tion (2 specimens), and eosinophils (2 specimens) were
less frequent findings (Figures 4–6). No explanted Cor-
Matrix material showed evidence of ingrowth of native
cells or transformation into cardiac tissue at a median of
21 months after implantation.Ta
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The potential for regeneration of native cardiac tissue
in humans with CorMatrix remains unclear. To our
Fig 3. (A) Low-power magnification with hematoxylin and eosin
(H&E) stain showing section of the CorMatrix patch with a band of
chronic inflammation and aggregates of histiocytes. (B) High-power
magnification with H&E stain showing a section of the CorMatrix
patch. This photomicrograph highlights the foreign body
multinucleated giant cell reaction.
Fig 4. Trichrome stain at low-power magnification highlighting the
acellular CorMatrix and the associated fibrosis.
Fig 5. Movat pentachrome stain at low-power magnification with
disorganized elastic fibers (stained black).
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evaluation of explanted intracardiac CorMatrix patches
in children with congenital heart disease. In 100% of
explanted patches, chronic inflammation and scar were
identified with no evidence of native tissue ingrowth or
regeneration. However, patches performed well in the
HFP baffle application and remained pliable and largely
without calcification.
CorMatrix ECM has been marketed as an intracardiac
patch material that can generate new healthy tissue
because it is completely resorbed over time [7]. The
proposed mechanism is that the SIS ECM elicits a
regenerative pathway that is immune-mediated and
provides a scaffold for native tissue ingrowth [1].
Early animal studies of SIS products were encour-
aging [1, 8–12]. Badylak and colleagues [1] used circular
patches created from sheets of ECM derived fromporcine small intestinal submucosa or porcine urinary
bladder matrix to repair full-thickness defects of
the right ventricular anterior walls of six pigs. They re-
ported complete replacement of the ECM with a mixture
of tissue types, including cartilage and contractile
myocardial tissue [1].
In general, experimental animal models with SIS ECM
for cardiac use have involved suturing the patch material
to an area of induced full-thickness injury [1]. In our
study, as would be the case in a typical atrial septal defect
closure in humans, patches are sewn to uninjured tissue
with an intact endothelium. The process of creating a
cardiac defect in animal models initiates an inflammatory
pathway that could potentially contribute to a difference
in findings. Future studies to investigate the role of su-
turing the patch to an edge of cut myocardium, as
opposed to an intact endothelialized surface such as the
right atrial wall, may be useful.
Fig 6. (A) Low-power and (B) high-power hematoxylin and eosin
stain showing membranous fibroconnective tissue with mild chronic
inflammation and dystrophic calcification (arrow).
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TMost specimens in this study demonstrated a robust
foreign body giant cell reaction to the CorMatrix patch,
similar to the findings of Woo and colleagues [2] and
Rosario and colleagues [3]. The appearance of the
aggregate of histiocytes (Figs 3A, 3B) is similar to what
would be expected with arteritis within the media of a
large vessel wall. Although elastic fibers were seen in two
cases on pentachrome staining, they were disorganized,
not well defined, and did not form a distinct layer (Fig 5).
In addition, the background of mucin-containing ground
substance, staining light blue on pentachrome stain, has
an appearance similar to a fibrinous exudate. These
findings do not support the theory that the CorMatrix was
in the process of forming an organized, elastic, or
muscular tissue layer such as atrial wall.
Badylak and colleagues [13] suggested that the forces
present in the mechanical environment might affect the
ability of SIS ECM products to remodel. Because our
patches were exposed to a low-pressure system, it is
possible that the lack of mechanical loading contributed
to a microenvironment that was not conducive to
remodeling in the time frame studied.
In the current study, the median time patches spent
in vivo (21 months) is greater than previously
published reports, and all were removed electively [4, 14,
15]. In general, time in vivo in prior reports has been short,
and most patches were removed for failure [4, 5, 14–16].
Additional strengths of this study are the homogeneity ofthe patient population, the standardization of the im-
plantation technique, and the consistent site of implan-
tation within the right atrium. Prior studies of explanted
CorMatrix represent a mix of patient ages and implanta-
tion sites [2–4, 15, 17]. Although CorMatrix is only
approved as a pericardial replacement or for intracardiac
repair, sites of implantation from prior reports of
explanted CorMatrix vary widely from the right ventric-
ular outflow tract, the mitral valve, pulmonary artery,
pulmonary valve, and aortic arch [2–4, 14, 15, 18, 19].
As has been demonstrated, CorMatrix may be a
clinically suitable patch material for the closure of septal
defects and reconstruction of the great vessels [15, 19].
Note that, in some studies, the tissues were not
examined for transformation, only for clinical efficacy
[16, 18]. Although some investigators have noted
suboptimal functional performance of CorMatrix when
used for pulmonary artery wall reconstruction, for
example, most studies have found that CorMatrix
patches remained pliable and did not exhibit calcifi-
cation at mid-term follow-up, much like our experience
[3, 15, 18–20]. In the current study, CorMatrix performed
well as a HFP baffle, but there is no evidence in our
study that CorMatrix demonstrates regenerative prop-
erties in humans.References
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diovasc Surg 2014;148:1769–70.DISCUSSIONDR ALI DODGE-KHATAMI (Jackson, MS): That was a beautiful
presentation. Congratulations on your results. As you
mentioned, a lot of the things that have been published on
CorMatrix are kind of retrospective and have almost the feel of
the believers and the nonbelievers of CorMatrix; some saying
that it is great stuff, and others saying that it is just as good as any
other patch material.
Based on the study that you did, which is very controlled, the
patches are in a low-pressure system. That may somehow in-
fluence your results. To the believers of CorMatrix, do you think
that part of the success would be the fact that they are implanting
CorMatrix as part of aortic valve repairs or conduit substitutes?
Do you think pressure or volume can play a role as to how
CorMatrix behaves?
DR NELSON: In other words, do I think that it would be more
successful in native tissue regeneration in a higher pressure
system?
I think there is a lot of evidence that looks at explanted valve
repair specimens which does not show native tissue remodeling
either. For the low-pressure example, in the dog studies that
were referenced in the CorMatrix product brochure, there were
ASD patches placed in 2 dogs and right ventricular free wall
patches in 2 other dogs. When explanted, by that report, they
were completely indistinguishable from otherwise normal car-
diac tissue.
The high-pressure example was looked at by Zaidi in 2014, and
those aortic and mitral valve specimens were basically the results
we have shown here. So no, I do not think so.
DR ANDREW LODGE (Durham, NC): I have always been con-
cerned that implanting this material as a patch where it is not
sewn to the cut edge could affect the ability for native tissue to
replace the patch. So the first question I have is: Do you think
that the fact that this patch was sewn to an endothelialized sur-
face could have had an impact on what you saw?
And the second is: Do you have any experience explanting
patches that are sewn to a cut surface, such as a ventriculotomy
or an arterial wall, that have shown different results?
DR NELSON: I will answer your second question first. No
experience in the evaluation of explanted patches that were sewn
to a cut edge.
To answer your first question, I think that it is possible. And in
those studies I mentioned in dogs, those ASDs had been created
for that model; therefore, there was a cut edge. Whereas in our
example, you are right, with the perpendicular attachment of thepatch to the right atrial wall it is an otherwise undisturbed, uncut
endothelialized surface. So I suppose that is a possible explana-
tion, although I reserve my enthusiasm.
DR MUHAMMAD MUMTAZ (San Antonio, TX): I have two
questions. One is that in your histopathologic studies did you see
any evidence of neovascularization of this tissue?
DR NELSON: We did not.
DR MUMTAZ: Did you look for that?
DR NELSON: We did.
DR MUMTAZ: And the second question is, which I’m assuming
the answer would be yes, is that at the time when you were
putting this patch, at the time of hemi-Fontan, let’s suppose that
patch size was X, then by the time you took it out the child had
grown and so the actual diameter of the patch is now larger than
when it was placed. Did you look at that? And this may not
represent growth, I understand that, but just in terms of plain
geometry of the patch, the size that was put in and the size that
was explanted, was there a difference?
DR NELSON: There was a difference. The explanted patches
were slightly smaller. They appeared whitish on the gross in-
spection, and they did appear slightly contracted.
DR MUMTAZ: So that is interesting. My own observation is that
they are not smaller but they have actually grown to the size of
whatever structure they are sutured to. Whereas if it was actually
smaller, would you expect the hemi-Fontan to develop a
gradient? I’m a little surprised by your answer.
DR NELSON: I would not expect a gradient in the hemi-Fontan
pathway just by nature of the flow patterns and the position of
the baffle which just really creates a barrier between the superior
venocaval-pulmonary artery junction and the body of the right
atrium. So contraction of this patch in that location would not
cause obstruction to flow there. I would also say that the degree
of contraction was almost imperceptible, but we were looking
really hard at that. And the difference in the size of the right
atrium was not of clinical significance.
DR CONSTANTINE MAVROUDIS (Orlando, FL): This was a
delightful presentation with excellent data. The fact that you only
have a few patients, 10 or 12, should not matter at all. I think you
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speak for itself.
However, I have a question on what you are doing now,
because that might be telling to the audience. I think there is a
bias either for or against these kinds of modified pericardial
patches. So the question for you is, what are you using now?
DR NELSON: We have returned to using PTFE for this patch in
this position.
DR JOHN E. MAYER (Boston, MA): I would say I am not
surprised by your findings. I think the question about whetherthe tissue is going to shrink or stretch, or I hesitate to use the
word, grow, is clearly going to depend on the hemodynamic
forces to which the material is subjected. I think the important
thing is that you have demonstrated quite clearly this is
nonliving tissue. Nonliving tissue that is continuously flexed or
stretched is going to stretch out and get bigger. If it is not
subjected to those forces, then it is likely to shrink as a part of
the inflammatory response to this foreign body. I think the
results that you show are exactly predictable if viewed from
that perspective.
DR NELSON: Thank you for your comments.C
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